# SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

> **NCT06889493** · PHASE1 · RECRUITING · sponsor: **Peter Hosein, MD** · enrollment: 36 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma
- Neuroendocrine Tumors

## Interventions

- **BIOLOGICAL:** Seneca Valley Virus-001 (SVV-001)
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06889493
- **Lead sponsor:** Peter Hosein, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889493, "SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06889493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*